Psychotherapy Intervention for Latinos With Advanced Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04015609 |
|
Recruitment Status :
Recruiting
First Posted : July 11, 2019
Last Update Posted : June 14, 2022
|
Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Lincoln Medical and Mental Health Center
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus on Latinos. We are interested in understanding what affects Latino patients' quality of life, and how to improve it
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Solid Tumor Solid Tumor, Adult Solid Tumor, Unspecified, Adult | Behavioral: Meaning Centered Psychotherapy for Latinos Behavioral: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale Behavioral: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients Behavioral: Pre-assessment questionnaire | Not Applicable |
Overview of the Study. This project has four phases. In the first two phases the study team will work to gain an understanding of the sources of meaning, hope, legacy and identity in Latino patients with advanced cancer; and to explore the acceptability and feasibility of applying IMCP to Latinos diagnosed with advanced cancer. A convergent mixed-methods design will be utilized with a sample of 155 Latino patients diagnosed with advanced cancer for the quantitative phase, and a nested cohort of 14-20 for the qualitative phase from two cancer centers in New York City: Memorial Sloan Kettering Cancer Center (MSKCC) and Lincoln Medical and Mental Health Center (LMC), a public hospital localized in a Latino-dense region. We will also recruit eligible cancer patients serviced through Dr. Gany's Intergrated Cancer Care Access Network (ICCAN). The Integrated Cancer Care Access Network (ICCAN) of MSKCC's Immigrant Health and Cancer Disparities Service (IHCD) enrolls patients at eleven hospital-based cancer clinics in New York City with large numbers of immigrant and low-income patients. ICCAN uses bilingual Access Facilitators to assist patients in accessing and utilizing health, social, and financial services. Identified needs of the patients, range from psychosocial support, to health literacy, child care, financial, housing and legal concerns. Patients enrolled to the ICCAN program are actively obtaining support from Access Facilitators throughout their treatment period. Access Facilitator will refer eligible patients to the study team for recruitment.
Before moving to phase 3, we will adapt and transcreate (the source text is rewritten to convey the concepts and achieve the aims of the source text, while accounting for both language and cultural considerations) the manual based on the phase 1 and 2 findings. In the third phase (Key Informant feedback), mental health providers will be interviewed to explore additional needed adaptations. The fourth phase will consist of pre-piloting or interviewing patients to assess the comprehension and acceptability of the adapted intervention.
Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 190 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | Adaptation and Pilot Feasibility of a Psychotherapy Intervention for Latinos With Advanced Cancer |
| Actual Study Start Date : | April 20, 2015 |
| Estimated Primary Completion Date : | August 31, 2023 |
| Estimated Study Completion Date : | August 31, 2023 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Meaning Centered Psychotherapy for Latinos (MCP-L) |
Behavioral: Meaning Centered Psychotherapy for Latinos
MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
Other Name: MCP-L Behavioral: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale Determines the degree of spiritual well-being Behavioral: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization. Behavioral: Pre-assessment questionnaire Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components. |
| Active Comparator: Control |
Behavioral: Meaning Centered Psychotherapy for Latinos
MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
Other Name: MCP-L Behavioral: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale Determines the degree of spiritual well-being Behavioral: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization. Behavioral: Pre-assessment questionnaire Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components. |
Primary Outcome Measures :
- Spiritual Well-Being measured with the FACIT Spiritual Well-Being Scale [ Time Frame: Change from baseline to post assessment 7-14 weeks after ]FACIT Spiritual Well-Being Scale is a brief self-report measure designed to assess the nature and extent of individual spiritual well-being. This measure, which generates two sub-scales, one corresponding to Faith (the importance of faith and spirituality) and a second assessing Meaning-Peace (one sense of meaning and purpose in life), has been demonstrated to have strong internal reliability for both the total score as well as each subscale (coefficient alpha equals .87 for the total scale, .88 for the faith factor and .81 for the meaning factor). In additional, strong support for the external validity of this measure has been demonstrated in a several large samples of cancer and AIDS patients and with Spanish speaking populations.
Secondary Outcome Measures :
- Depression and Anxiety measured with the Hospital Anxiety and Depression Scale [ Time Frame: Change from baseline to post assessment 7-14 weeks after ]The Hospital Anxiety and Depression Scale (HADS) is a validated scale used to measure anxiety and depression. This scale has been validated against structured or semi-structured clinical interviews, the gold standard for the assessment of mental disorders, in a significant number of studies. Further strengths of this scale for the assessment of emotional distress in cancer patients stem from the joint assessment of anxiety and depressive symptoms without referring to physical symptoms of anxiety or depression. Given the high comorbidity of anxiety of cancer as well as the systematic exclusion of confounding physical symptoms, the scale seems especially appropriate for use in this patient group. The HADS consists of 14 items which reflect a 7-item anxiety and a 7-item depression subscale. This scale has sound psychometric properties in Spanish.
- Hopelessness measured with the Beck Hopelessness Scale [ Time Frame: Change from baseline to post assessment 7-14 weeks after ]The Beck Hopelessness Scale (BHS) comprises 20 true/false questions that assess degree of pessimism and hopelessness. Several studies have demonstrated a high degree of internal consistency and construct validity. Scores ranging from 4 to 8 typically indicate a "mild" degree of hopelessness, 9 to 12 correspond to "moderate" hopelessness, and scores about 12 reflect "severe" levels of hopelessness.
- Quality of life measured with the FACIT Spiritual Well-Being Scale [ Time Frame: Change from baseline to post assessment 7-14 weeks after ]The FACIT Spiritual Well-Being Scale (FACIT-Sp-12) is a brief self-report measure designed to assess the nature and extent of individual's spiritual well-being. This measure (range 0-48), which generates two sub-scales, Faith (the importance of faith/spirituality, range 0-16) and Meaning /Peace (one's sense of meaning and purpose in life, range 0-32). The total score for the FACIT-Sp scale is the sum of the two subscales Faith and Meaning /Peace. It has been demonstrated to have strong internal reliability for both the total score as well as each subscale (coefficient alpha = .87 for the total scale, .88 for the faith factor and .81 for the meaning factor). Higher scores represent a higher level of spiritual well-being, faith or meaning-peace. In addition, strong support for the external validity of this measure has been demonstrated in a several large samples of cancer and AIDS patients and with Spanish speaking populations. Administration time takes approximately 4 minutes.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Phase I: Quantitative
- Diagnosed with stages III or IV solid tumor cancer *(as per self report for ICCAN patients)
- Age 18 or older
- As per self report, Latino/a or Hispanic ethnicity
- As per self report, fluent in oral Spanish (monolingual) or fluent in oral Spanish and English (bilingual)
Phase 2: Qualitative
- Enrolled in the quantitative phase of study (as seen above)
- Completes the quantitative phase questionnaire package
- Scores above or below the threshold for the Distress Thermometer (DT≥4 or ≤3)
- In the judgment of the investigator, willing and able to be interviewed in Spanish only
- Agrees to be audio- recorded
Phase 3: Provider Feedback
- Professionals working in the mental health field;
- Have a caseload of five or more Latino cancer patients per month
- Able to communicate and read in Spanish
- Agrees to be audio or video-recorded
Phase 4: Patient Feedback
- Diagnosed with stages III or IV solid tumor cancer *(as per self report for ICCAN patients)
- Age 18 or older
- As per self report, Latino/a or Hispanic ethnicity
- In the judgment of the investigator, willing and able to be interviewed in Spanish only
- Agrees to be audio-recorded
Exclusion Criteria:
Phase 1: Quantitative
- In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
- In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
Phase 2: Qualitative
- In the judgment of the treating physician and/or the consenting professional, presence of significant cognitive impairment (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection
- In the judgment of the consenting professional, significant or major disabling medical or psychiatric condition sufficient to preclude meaningful informed consent, interview, or completion of assessment measures (patients whose psychiatric disorder is well controlled by treatment will be eligible)
Phase 4: Patient Feedback
- Diagnosed with a major disabling medical or psychiatric condition
- Unable to understand the consent procedure
- Too ill to participate, all as reported by the patient and/or determined by the investigator's judgment.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04015609
Contacts
| Contact: Rosario Costas-Muniz, PhD | 646-888-8062 | costasmr@mskcc.org | |
| Contact: William Breitbart, MD | 646-888-0020 | breitbaw@mskcc.org |
Locations
| United States, New York | |
| Lincoln Medical and Mental Health Center | Recruiting |
| Bronx, New York, United States | |
| Contact: Caroline Hwang, MD 718-579-5000 | |
| Memorial Sloan Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Rosario Costas-Muniz, PhD 646-888-8062 | |
| Ralph Lauren Center for Cancer Care and Prevention | Recruiting |
| New York, New York, United States | |
| Contact: Rosa Nouvini, MD 646-608-0279 | |
| Puerto Rico | |
| Ponce Health Sciences University | Recruiting |
| Ponce, Puerto Rico, 00732 | |
| Contact: Eida Castro-Figueroa, PhD ecastro@psm.edu | |
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Lincoln Medical and Mental Health Center
Investigators
| Principal Investigator: | Rosario Costas-Muniz, PhD | Memorial Sloan Kettering Cancer Center |
Additional Information:
| Responsible Party: | Memorial Sloan Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT04015609 |
| Other Study ID Numbers: |
15-076 |
| First Posted: | July 11, 2019 Key Record Dates |
| Last Update Posted: | June 14, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Memorial Sloan Kettering Cancer Center:
|
Stage III solid tumor cancer Stage IV solid tumor cancer Stage III cancer Stage IV cancer |
Spanish Memorial Sloan Kettering Cancer Center 15-076 |
Additional relevant MeSH terms:
|
Neoplasms |